Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A recent cross-sectional study reveals that alterations in gut microbiota correlate more strongly with impaired health-related quality of life in IBD patients than clinical disease activity, suggesting novel microbial therapeutic targets be
The FDA has approved golimumab (Simponi) for treating moderately to severely active ulcerative colitis in children weighing at least 15 kg, based on the PURSUIT 2 phase 3 study demonstrating significant clinical remission and safety.
A large Nordic study finds menopausal hormone therapy reduces the risk of esophageal and gastric cancers by up to 30%, especially with combined estrogen-progestin systemic formulations.
A recent trial assessing intravenous versus oral rehydration in children with severe acute malnutrition and gastroenteritis found no mortality difference at 96 hours, challenging fears of fluid overload and supporting cautious consideration
A 45-year-old male presents with cholestatic liver enzyme elevation and pruritus, diagnosed with primary sclerosing cholangitis confirmed by imaging and liver biopsy. Clinical management and prognosis are discussed.
Cendakimab, a monoclonal antibody targeting IL-13, shows significant improvements in symptoms, histologic response, and endoscopic features in eosinophilic esophagitis, with a tolerable safety profile through 48 weeks.
This study reveals that elevated reflux secondary bile acids in Barrett’s esophagus influence the esophageal microbiome and gene expression, highlighting potential mechanisms underpinning progression to esophageal adenocarcinoma.
Intercept Pharmaceuticals withdraws OCALIVA from the US market following FDA demands due to safety concerns and lack of proven efficacy in PBC, prompting suspension of related clinical trials and significant shifts in therapeutic landscape.
AI-assisted digital pathology improves inter-pathologist agreement on fibrosis staging in metabolic dysfunction-associated steatohepatitis (MASH), enhancing clinical trial accuracy and efficiency.
A phase Ib/IIa trial demonstrated that HEC88473, a novel GLP-1/FGF21 dual agonist, is generally safe, effectively reduces liver fat, and improves glycemic and lipid profiles in MASLD patients with type 2 diabetes within five weeks of treatm
AZD2693, a liver-directed antisense oligonucleotide, safely reduces PNPLA3 expression and liver fat in homozygous PNPLA3 148M carriers with metabolic dysfunction-associated steatohepatitis, signaling promise for precision treatment in this
This phase I study evaluates rapirosiran, an RNA interference therapeutic targeting HSD17B13, demonstrating safety, tolerability, and significant liver mRNA reduction in patients with metabolic dysfunction-associated steatohepatitis (MASH).
The THEMATIC phase II trial demonstrates that fecal microbiota transplantation (FMT) is safe and reduces HE recurrence in cirrhosis, independent of dose, route, or donor diet, with gut microbiota engraftment linked to clinical outcomes.
Lanifibranor, a pan-PPAR agonist, significantly reduces liver fat and improves insulin sensitivity at multiple tissue sites in type 2 diabetes patients with MASLD, offering a new therapeutic avenue to address underlying metabolic dysfunctio
A phase IIb trial of the FFAR1/FFAR4 agonist icosabutate in MASH shows encouraging fibrosis improvement and biomarker responses despite not meeting the primary endpoint, supporting further development.
The phase IIb ICONA trial evaluated icosabutate, a dual FFAR1/FFAR4 agonist, in patients with MASH, showing fibrosis improvement without meeting the primary endpoint, and supporting further development particularly in advanced fibrosis and
Losing weight doesn’t always mean improving fatty liver disease. Discover why strict diets lacking essential proteins can worsen liver health and learn practical dietary strategies to manage and reverse fatty liver effectively.
Intraduodenal calcium at doses up to 1000 mg amplifies the anorexigenic effects of L-tryptophan by boosting gut hormones CCK, GLP-1, and PYY, reducing energy intake in obese males, highlighting a novel adjunctive approach for appetite regul
A multicenter trial demonstrated that integrating AI-based computer-aided detection with water exchange colonoscopy significantly increases adenomas per colonoscopy without prolonging procedure time or increasing non-neoplastic lesion detec
A randomized trial demonstrates that leaving small non-neoplastic colorectal polyps in situ with AI-assisted optical diagnosis is as safe and effective as systematic removal, supporting less invasive colonoscopy strategies.
Open language-specific specialty feeds and department pages.